TransMedics Group, Inc. (TMDX) Quarterly Net Income
The quarterly net income for TransMedics Group, Inc. (TMDX) is $7.32M with a period-over-period change of (93.06%). Quarterly net income is profit after expenses, taxes, interest, and other items for the latest fiscal quarter.
TMDX Quarterly Net Income Chart
Quarterly Net Income History
| Date | Quarterly Net Income | % Change |
|---|---|---|
| Q1 2026 | $7.32M | (93.06%) |
| Q4 2025 | $105.38M | +333.34% |
| Q3 2025 | $24.32M | (30.33%) |
| Q2 2025 | $34.91M | +35.92% |
| Q1 2025 | $25.68M | +274.54% |
| Q4 2024 | $6.86M | +62.64% |
| Q3 2024 | $4.22M | (65.43%) |
| Q2 2024 | $12.19M | (0.02%) |
| Q1 2024 | $12.20M | +202.58% |
| Q4 2023 | $4.03M | +115.86% |
| Q3 2023 | ($25.42M) | (2439.66%) |
| Q2 2023 | ($1.00M) | +62.03% |
| Q1 2023 | ($2.64M) | +60.77% |
| Q4 2022 | ($6.72M) | +9.51% |
| Q3 2022 | ($7.43M) | +35.55% |
| Q2 2022 | ($11.52M) | (9.10%) |
| Q1 2022 | ($10.56M) | +16.62% |
| Q4 2021 | ($12.67M) | +2.27% |
| Q3 2021 | ($12.96M) | (21.50%) |
| Q2 2021 | ($10.67M) | (34.75%) |
| Q1 2021 | ($7.92M) | (25.45%) |
| Q4 2020 | ($6.31M) | (24.04%) |
| Q3 2020 | ($5.09M) | +40.12% |
| Q2 2020 | ($8.50M) | +4.01% |
| Q1 2020 | ($8.85M) | +3.54% |
| Q4 2019 | ($9.18M) | (10.83%) |
| Q3 2019 | ($8.28M) | +9.95% |
| Q2 2019 | ($9.20M) | (33.36%) |
| Q1 2019 | ($6.89M) | +9.69% |
| Q4 2018 | ($7.63M) | (49.56%) |
| Q3 2018 | ($5.11M) | +16.52% |
| Q2 2018 | ($6.12M) | (24.77%) |
| Q1 2018 | ($4.90M) | (5.44%) |
| Q4 2017 | ($4.65M) | +3.29% |
| Q3 2017 | ($4.81M) | +16.33% |
| Q2 2017 | ($5.74M) | (1.05%) |
| Q1 2017 | ($5.68M) | - |
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein